OncoSec Medical Inc (ONCSQ)

[chickpea598]

JOURNAL OF CLINICAL ONCOLOGY article from 2015 titled:
IMMUNE CHECKPOINT BLOCKADE IN CANCER THERAPY.

Lots of clinical data in this article.

jco.ascopubs.org/content/early/2015/01/20/JCO.2014.59.4358.full



I especially like this part:

Biomarkers Associated With Disease Outcome
Treatment with immunologic checkpoint blockade would ideally be matched to patients who are most likely to benefit and least likely to experience adverse effects. The efficacy of CTLA-4 and PD-1 blockade also somewhat varies among different tumor types, and better understanding these differences would enhance the efficacy of this treatment modality. At this time, no single immunologic or tumoral characteristic in a patient has been found to solely determine response to an immunotherapeutic agent.


ONCOSEC! WE GOT THIS!